ѻý

<ѻý class="page-title">Oncology/Hematology

Renal Cell Carcinoma

<ѻý class="page-description">

More in Renal Cell Carcinoma

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

Sep 13, 2024
ESMO over a photo of Fira Barcelona Gran Via in Barcelona, Spain.
Top Cancer Centers; Phase III Win in Prostate Cancer; Screening Recs for Anal Cancer

News, features, and commentary about cancer-related issues

Jul 19, 2024
Onco Break over a computer rendering of a cancer cell.
Surveillance for Small Renal Masses No Detriment to Nephron-Sparing Surgery

Similar outcomes with immediate versus delayed surgery, supporting use of active surveillance

May 06, 2024
AUA over a photo of Henry B. González Convention Center in San Antonio, TX
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS

Jan 28, 2024
GuCS logo over building
Futile Immunotherapy for Cancer Grows More Common

Occurs most often at non-academic and low-volume centers

Jan 04, 2024
An image of a senior man laying on a hospital bed with an intravenous line attached to his arm.
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF

Dec 15, 2023
FDA approved belzutifan (Welireg) over a computer rendering 0f a tumor on a kidney.
'Watch and Wait' With Small Renal Masses: When and How Should Docs Intervene?

Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance

Dec 04, 2023
SUO over a photo of the Omni Shoreham Hotel in Washington, DC.
'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma

Potential standard of care after current therapies, but key obstacles remain in the way

Nov 15, 2023
IKCS over a photo of Omni Nashville Hotel, Nashville, Tennessee
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

Nov 14, 2023
IKCS over a photo of Omni Nashville Hotel, Nashville, Tennessee
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose

A quarter of patients responded whether at the recommended or higher dose

Nov 13, 2023
IKCS over a photo of Omni Nashville Hotel, Nashville, Tennessee
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma

Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients

Nov 11, 2023
IKCS over a photo of Omni Nashville Hotel, Nashville, Tennessee
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

Oct 24, 2023
ESMO over a photo of IFEMA Madrid in Spain.
SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer

Phase II study shows 100% local control and cancer-specific survival after more than 3 years

Oct 01, 2023
image
Adjuvant Everolimus Falls Short in High-Risk Renal Cancer

However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy

Jul 31, 2023
A photo of a box of Afinitor tablets over a computer rendering of a kidney with a tumor.
More in Renal Cell Carcinoma